KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Cash from Operations (2017 - 2026)

Amneal Pharmaceuticals has reported Cash from Operations over the past 9 years, most recently at 130315000.0 for Q4 2025.

For Q4 2025, Cash from Operations rose 10.36% year-over-year to 130315000.0; the TTM value through Dec 2025 reached 339992000.0, up 15.21%, while the annual FY2025 figure was 339992000.0, 15.21% up from the prior year.
Cash from Operations for Q4 2025 was 130315000.0 at Amneal Pharmaceuticals, up from 118450000.0 in the prior quarter.
Over five years, Cash from Operations peaked at 148128000.0 in Q1 2021 and troughed at 125521000.0 in Q2 2022.
A 5-year average of 64379400.0 and a median of 83091500.0 in 2021 define the central range for Cash from Operations.
Biggest five-year swings in Cash from Operations: plummeted 141.7% in 2022 and later skyrocketed 683.13% in 2023.
Year by year, Cash from Operations stood at 63261000.0 in 2021, then tumbled by 136.82% to 23292000.0 in 2022, then skyrocketed by 683.13% to 135823000.0 in 2023, then fell by 13.06% to 118078000.0 in 2024, then grew by 10.36% to 130315000.0 in 2025.
Business Quant data shows Cash from Operations for AMRX at 130315000.0 in Q4 2025, 118450000.0 in Q3 2025, and 83819000.0 in Q2 2025.